Hsbc Holdings PLC purchased a new position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 48,341 shares of the biotechnology company’s stock, valued at approximately $464,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Corient Private Wealth LLC boosted its holdings in Anika Therapeutics by 4.3% in the fourth quarter. Corient Private Wealth LLC now owns 32,224 shares of the biotechnology company’s stock worth $310,000 after purchasing an additional 1,324 shares in the last quarter. Invesco Ltd. raised its holdings in Anika Therapeutics by 7.9% during the fourth quarter. Invesco Ltd. now owns 25,272 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 1,843 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Anika Therapeutics during the fourth quarter valued at about $122,000. NewEdge Advisors LLC acquired a new stake in shares of Anika Therapeutics in the fourth quarter worth about $139,000. Finally, XTX Topco Ltd lifted its position in shares of Anika Therapeutics by 74.3% in the fourth quarter. XTX Topco Ltd now owns 22,252 shares of the biotechnology company’s stock worth $214,000 after buying an additional 9,482 shares during the last quarter. Institutional investors own 91.53% of the company’s stock.
Analyst Upgrades and Downgrades
ANIK has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Anika Therapeutics in a report on Wednesday, June 24th. Wall Street Zen lowered Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $17.00.
Anika Therapeutics Price Performance
Shares of ANIK opened at $15.82 on Friday. The company has a market capitalization of $210.56 million, a PE ratio of -20.03 and a beta of 0.23. Anika Therapeutics Inc. has a one year low of $7.87 and a one year high of $16.49. The company’s fifty day moving average price is $14.96 and its 200 day moving average price is $13.30.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.34. The company had revenue of $29.61 million during the quarter, compared to analysts’ expectations of $28.14 million. Anika Therapeutics had a negative net margin of 9.52% and a negative return on equity of 5.90%. Analysts anticipate that Anika Therapeutics Inc. will post -0.74 earnings per share for the current year.
Insider Activity at Anika Therapeutics
In other Anika Therapeutics news, Director John B. Henneman III bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was purchased at an average price of $14.66 per share, for a total transaction of $73,300.00. Following the purchase, the director directly owned 54,871 shares in the company, valued at $804,408.86. This trade represents a 10.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen D. Griffin bought 12,200 shares of the stock in a transaction on Thursday, April 30th. The stock was acquired at an average cost of $12.29 per share, for a total transaction of $149,938.00. Following the acquisition, the chief executive officer directly owned 36,163 shares in the company, valued at approximately $444,443.27. The trade was a 50.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 12.08% of the stock is owned by corporate insiders.
About Anika Therapeutics
Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.
The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.
Read More
- Five stocks we like better than Anika Therapeutics
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK – Free Report).
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
